NGL FINE-CHEM LIMITED

Regd Office: 301, E-Square, Subhash Road Vile Parle (East), Mumbai-400057 CIN: L24110MH1981PLC025884



UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER 2015

unees in lakhs

							upees in lakhs
		Quarter ended			Nine Month Ended		Year ended
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
		(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	a. Net Sales / Income from Operations	2,234.03	2,276.22	1,893.45	6,919.63	6,125.88	8,634.22
<u> </u>	b. Other Operating Income	36.16	20.89	28.36	110.89	181.18	198.57
	Total Income	2,270.19	2,297.11	1,921.81	7,030.52	6,307.06	8,832.79
2	Total Expenditure :						
	a. Consumption of Raw Material	890.73	1,060.07	1,141.53	3,016.33	3,166.68	4,398.70
	b. (Increase)/Decrease in stock in trade and work in progress	80.75	(110.90)	(185.34)	(3.61)	(136.01)	(234.73)
	c. Employees Cost	248.52	315.95	216.35	843.24	663.60	940.24
	d. Depreciation	65.94	65.25	65.78	195.21	198.53	259.68
	e. Other Expenditure	561.13	530.91	607.03	1,664.40	1,667.25	2,262.28
	g. Total	1,847.07	1,861.28	1,845.35	5,715.57	5,560.05	7,626.17
3	Profit from operations before other income, finance costs (1 - 2)	423.12	435.83	76.46	1,314.95	747.01	1,206.62
4	Other Income	2.66	4.28	3.00	9.46	7.34	13.14
5	Profit from ordinary activities before finance costs (3 + 4)	425.78	440.11	79.46	1,324.41	754.35	1,219.76
6	Finance Costs	(17.24)	(28.31)	(26.75)	(75.92)	(100.51)	(125.47)
7	Profit from ordinary activities before tax (5 - 6)	408.54	411.80	52.71	1,248.49	653.84	1,094.29
8	Exceptional items	-	-	191.62	-	191.62	191.62
9	Net Profit for the Period (7 - 8)	408.54	411.80	244.33	1,248.49	845.46	1,285.91
10	Tax Expense	(131.34)	(156.32)	(101.23)	(446.06)	(298.03)	(452.90)
11	Net Profit (9 - 10)	277.20	255.48	143.10	802.43	547.43	833.01
12	Extraordinery items (net of tax expense)		-	-		-	-
13	Net Profit / Loss for the period (11-12)	277.20	255.48	143.10	802.43	547.43	833.01
14	Share of Profit / loss of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit/loss of	277.20	255.48	143.10	802.43	547.43	833.01
	associates (13-14-15)						
17	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	308.90	308.90
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	N.A	N.A	2,972.73
19	Earnings Per Share (EPS)						
	a) Basic	4.49	4.14	2.32	12.99	8.86	13.48
	b) Diluted	4.49	4.14	2.32	12.99	8.86	13.48

- 1. The above results were reviewed by the Audit Committee and have been taken on record by the Board of Directors of the Company at their meeting held on February 9, 2016
- 2 The Statutory Auditors have carried out a limited review of the quarter & nine months ended 31st December 2015
- The Company's operations consist only of one segment i.e. pharmaceuticals, hence Segment Reporting required under AS17 is not applicable.
- 5 The figures of the corresponding period have been regrouped wherever necessary.

For and On behalf of Board of Directors,

Mumbai February 9, 2016 Rahul Nachane *Managing Director* DIN: 00223346